Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962353 | 0.80 | CA2 (0.33) | CA2SOS1MEN1KMT2AADORA2A | |
| SCHEMBL25033941 | 0.76 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL21963358 | 0.73 | CA2 (0.36) | CA2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20680938 | 0.69 | CA2 (0.40) | CA2SOS1ALDH1A1KDM4EMAPT | |
| SCHEMBL21962847 | 0.69 | ALDH1A1 (0.57) | CA2ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL21962741 | 0.62 | HRH3 (0.40) | ALDH1A1HTTKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL25032671 | 0.62 | SMN1; SMN2 (0.31) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL9530416 | 0.61 | CA2 (1.00) | CA2 | |
| SCHEMBL21963195 | 0.60 | CYP11B1 (0.33) | CA2 | |
| SCHEMBL20698783 | 0.60 | PTGS2 (0.48) | CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1210/4885SOS1 3644/4885ALDH1A1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.